CORhum - Morbidity-mortality of COVID-19 in patients with chronic rheumatic disorder treated with immunosuppressants
Head :
LETAROUILLY Jean-Guillaume
Last update : 05/05/2021 | Version : 1 | ID : 73495
| General | |
| Identification | |
| Detailed name | Morbidity-mortality of COVID-19 in patients with chronic rheumatic disorder treated with immunosuppressants |
| Sign or acronym | CORhum |
| CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | CNIL 2021796 v 0, CPP CPP2020-06-056b, NCT04426279 |
| General Aspects | |
| Medical area |
Internal medicine Rheumatology |
| Study in connection with Covid-19 |
Yes |
| Pathology (details) | systemic lupus erythematosus, spondyloarthritis, rheumatoid arthritis |
| Keywords | systemic lupus erythematosus, spondyloarthritis, chronic rheumatic disorder, biological therapy, rheumatoid arthritis, immunosuppressants |
| Scientific investigator(s) (Contact) | |
| Name of the director | LETAROUILLY |
| Surname | Jean-Guillaume |
| Address | Service de Rhumatologie<br>Hôpital Roger Salengro<br>Rue Emile Laine<br>59037 Lille |
| Phone | 320446926 |
| jeanguillaume.letarouilly@chu-lille.fr | |
| Organization | Lille University Hospital |
| Collaborations | |
| Participation in projects, networks and consortia |
Yes |
| Funding | |
| Governance of the database | |
| Sponsor(s) or organisation(s) responsible | Lille University Hospital |
| Organisation status |
Public |
| Additional contact | |
| Main features | |
| Type of database | |
| Type of database |
Study databases |
| Study databases (details) |
Not-repeated cross-sectional studies (except case control studies) |
| Database recruitment is carried out as part of an interventional study |
No |
| Database objective | |
| Main objective | Estimate morbidity-mortality associated with COVID-19 in patients with chronic rheumatic disorder (CRD) receiving immunosuppressants (IS). |
| Inclusion criteria | Patients with RA on csDMARD +/- bDMARD or tsDMARD +/- corticosteroid therapy fulfilling 2010 ACR/EULAR classification criteria? Patients with SpA receiving bDMARD or tsDMARD +/- csDMARD +/- non-steroidal anti-inflammatory drugs fulfilling ASAS classification criteria? Patients with SLE receiving hydroxychloroquine +/- csDMARD +/- corticosteroid therapy +/- bDMARD fulfilling 2019 ACR/EULAR classification criteria |
| Population type | |
| Age |
Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) |
| Population covered |
Sick population |
| Pathology | L93 - Lupus erythematosus |
| M05-M14 - Inflammatory polyarthropathies | |
| Gender |
Male Woman |
| Geography area |
Local |
| French regions covered by the database |
Nord - Pas-de-Calais Picardie |
| Data collection | |
| Dates | |
| Size of the database | |
| Size of the database (number of individuals) |
[500-1000[ individuals |
| Details of the number of individuals | 1500 |
| Data | |
| Database activity |
Current data collection |
| Type of data collected |
Clinical data |
| Presence of a biobank |
No |
| Procedures | |
| Followed pathology | |
| Promotion and access | |
| Promotion | |
| Access |
